Detailed Information on Publication Record
2022
Autoimmunity, cancer and COVID‑19 abnormally activate wound healing pathways: critical role of inflammation
GÁL, Peter, Jan BRÁBEK, Michal HOLUB, Milan JAKOUBEK, Aleksi ŠEDO et. al.Basic information
Original name
Autoimmunity, cancer and COVID‑19 abnormally activate wound healing pathways: critical role of inflammation
Authors
GÁL, Peter (203 Czech Republic), Jan BRÁBEK (203 Czech Republic), Michal HOLUB (203 Czech Republic), Milan JAKOUBEK (203 Czech Republic), Aleksi ŠEDO (203 Czech Republic), Lukáš LACINA (203 Czech Republic), Karolina STRNADOVÁ (203 Czech Republic), Petr DUBOVÝ (203 Czech Republic, guarantor, belonging to the institution), Helena HORNYCHOVÁ (203 Czech Republic), Aleš RYŠKA (203 Czech Republic) and Karel SMETANA JR. (203 Czech Republic)
Edition
Histochemistry and Cell Biology, NEW YORK, SPRINGER, 2022, 0948-6143
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
10601 Cell biology
Country of publisher
Switzerland
Confidentiality degree
není předmětem státního či obchodního tajemství
References:
Impact factor
Impact factor: 2.300
RIV identification code
RIV/00216224:14110/22:00127917
Organization unit
Faculty of Medicine
UT WoS
000828939900001
Keywords in English
Wound healing; Granulation tissue; Peripheral nerve injury; Rheumatoid arthritis; Cancer stroma; SARSCoV- 2; Myofibroblast; IL-6; Inflammation
Tags
International impact, Reviewed
Změněno: 23/1/2023 10:32, Mgr. Tereza Miškechová
Abstract
V originále
Recent evidence indicates that targeting IL-6 provides broad therapeutic approaches to several diseases. In patients with cancer, autoimmune diseases, severe respiratory infections [e.g. coronavirus disease 2019 (COVID-19)] and wound healing, IL-6 plays a critical role in modulating the systemic and local microenvironment. Elevated serum levels of IL-6 interfere with the systemic immune response and are associated with disease progression and prognosis. As already noted, monoclonal antibodies blocking either IL-6 or binding of IL-6 to receptors have been used/tested successfully in the treatment of rheumatoid arthritis, many cancer types, and COVID-19. Therefore, in the present review, we compare the impact of IL-6 and anti-IL-6 therapy to demonstrate common (pathological) features of the studied diseases such as formation of granulation tissue with the presence of myofibroblasts and deposition of new extracellular matrix. We also discuss abnormal activation of other wound-healing-related pathways that have been implicated in autoimmune disorders, cancer or COVID-19.